Sokha Nhek1, Robert Clancy1, Kristen A Lee1, Nicole M Allen1, Tessa J Barrett1, Emanuela Marcantoni1, Janet Nwaukoni1, Sara Rasmussen1, Maya Rubin1, Jonathan D Newman1, Jill P Buyon1, Jeffrey S Berger2. 1. From the Department of Medicine, Divisions of Cardiology (S.N., K.A.L., N.M.A., T.J.B., E.M., M.R., J.D.N., J.S.B.), Hematology (J.S.B.), and Rheumatology (R.C., J.N., S.R., J.P.B.), New York University School of Medicine, New York. 2. From the Department of Medicine, Divisions of Cardiology (S.N., K.A.L., N.M.A., T.J.B., E.M., M.R., J.D.N., J.S.B.), Hematology (J.S.B.), and Rheumatology (R.C., J.N., S.R., J.P.B.), New York University School of Medicine, New York. Jeffrey.berger@nyumc.org.
Abstract
OBJECTIVE: Systemic lupus erythematosus (SLE) is associated with the premature development of cardiovascular disease. The platelet-endothelium interaction is important in the pathogenesis of cardiovascular disease. In this study, we investigated the platelet phenotype from patients with SLE and matched controls, and their effect on endothelial cells. APPROACH AND RESULTS: Platelet aggregability was measured in 54 SLE subjects off antiplatelet therapy (mean age 40.1±12.8 years; 82% female; 37% white) with age- and sex-matched controls. Platelets were coincubated with human umbilical vein endothelial cells (HUVECs) and changes to gene expression assessed by an RNA array and quantitative reverse transcription polymerase chain reaction. SLE disease activity index ranged from 0 to 22 (mean 5.1±3.9). Compared with controls, patients with SLE had significantly increased monocyte and leukocyte-platelet aggregation and platelet aggregation in response to submaximal agonist stimulation. An agnostic microarray of HUVECs cocultured with SLE platelets found a platelet-mediated effect on endothelial gene pathways involved in cell activation. Sera from SLE versus control subjects significantly increased (1) activation of control platelets; (2) platelet adhesion to HUVECs; (3) platelet-induced HUVEC gene expression of interleukin-8, and intercellular adhesion molecule 1; and (4) proinflammatory gene expression in HUVECs, mediated by interleukin-1β-dependent pathway. Incubation of SLE-activated platelets with an interleukin-1β-neutralizing antibody or HUVECs pretreated with interleukin-1 receptor antibodies attenuated the platelet-mediated activation of endothelial cells. CONCLUSIONS: Platelet activity measurements and subsequent interleukin-1β-dependent activation of the endothelium are increased in subjects with SLE. Platelet-endothelial interactions may play a role in the pathogenesis of cardiovascular disease in patients with SLE.
OBJECTIVE:Systemic lupus erythematosus (SLE) is associated with the premature development of cardiovascular disease. The platelet-endothelium interaction is important in the pathogenesis of cardiovascular disease. In this study, we investigated the platelet phenotype from patients with SLE and matched controls, and their effect on endothelial cells. APPROACH AND RESULTS: Platelet aggregability was measured in 54 SLE subjects off antiplatelet therapy (mean age 40.1±12.8 years; 82% female; 37% white) with age- and sex-matched controls. Platelets were coincubated with human umbilical vein endothelial cells (HUVECs) and changes to gene expression assessed by an RNA array and quantitative reverse transcription polymerase chain reaction. SLE disease activity index ranged from 0 to 22 (mean 5.1±3.9). Compared with controls, patients with SLE had significantly increased monocyte and leukocyte-platelet aggregation and platelet aggregation in response to submaximal agonist stimulation. An agnostic microarray of HUVECs cocultured with SLE platelets found a platelet-mediated effect on endothelial gene pathways involved in cell activation. Sera from SLE versus control subjects significantly increased (1) activation of control platelets; (2) platelet adhesion to HUVECs; (3) platelet-induced HUVEC gene expression of interleukin-8, and intercellular adhesion molecule 1; and (4) proinflammatory gene expression in HUVECs, mediated by interleukin-1β-dependent pathway. Incubation of SLE-activated platelets with an interleukin-1β-neutralizing antibody or HUVECs pretreated with interleukin-1 receptor antibodies attenuated the platelet-mediated activation of endothelial cells. CONCLUSIONS: Platelet activity measurements and subsequent interleukin-1β-dependent activation of the endothelium are increased in subjects with SLE. Platelet-endothelial interactions may play a role in the pathogenesis of cardiovascular disease in patients with SLE.
Authors: Lea M Beaulieu; Elaine Lin; Eric Mick; Milka Koupenova; Ellen O Weinberg; Carolyn D Kramer; Caroline A Genco; Kahraman Tanriverdi; Martin G Larson; Emelia J Benjamin; Jane E Freedman Journal: Arterioscler Thromb Vasc Biol Date: 2014-01-23 Impact factor: 8.311
Authors: Michelle Petri; Mimi Y Kim; Kenneth C Kalunian; Jennifer Grossman; Bevra H Hahn; Lisa R Sammaritano; Michael Lockshin; Joan T Merrill; H Michael Belmont; Anca D Askanase; W Joseph McCune; Michelene Hearth-Holmes; Mary Anne Dooley; Joan Von Feldt; Alan Friedman; Mark Tan; John Davis; Mary Cronin; Betty Diamond; Meggan Mackay; Lisa Sigler; Michael Fillius; Ann Rupel; Frederick Licciardi; Jill P Buyon Journal: N Engl J Med Date: 2005-12-15 Impact factor: 91.245
Authors: Jeannine S Navratil; Susan Manzi; Amy H Kao; Shanthi Krishnaswami; Chau-Ching Liu; Margie J Ruffing; Penny S Shaw; Abbey C Nilson; Emily R Dryden; Jeffrey J Johnson; Joseph M Ahearn Journal: Arthritis Rheum Date: 2006-02
Authors: Jeffrey S Berger; Richard C Becker; Cynthia Kuhn; Michael J Helms; Thomas L Ortel; Redford Williams Journal: Thromb Haemost Date: 2012-12-06 Impact factor: 5.249
Authors: Sucharita SenBanerjee; Zhiyong Lin; G Brandon Atkins; Daniel M Greif; Ravi M Rao; Ajay Kumar; Mark W Feinberg; Zhiping Chen; Daniel I Simon; F William Luscinskas; Thomas M Michel; Michael A Gimbrone; Guillermo García-Cardeña; Mukesh K Jain Journal: J Exp Med Date: 2004-05-10 Impact factor: 14.307
Authors: Michael S Garshick; Michael Tawil; Tessa J Barrett; Charissa M Salud-Gnilo; Michael Eppler; Angela Lee; Jose U Scher; Andrea L Neimann; Sanja Jelic; Nehal N Mehta; Edward A Fisher; James G Krueger; Jeffrey S Berger Journal: Arterioscler Thromb Vasc Biol Date: 2020-03-05 Impact factor: 8.311
Authors: Kelly E Johnson; Julia R Ceglowski; Harvey G Roweth; Jodi A Forward; Mason D Tippy; Saleh El-Husayni; Rajesh Kulenthirarajan; Michael W Malloy; Kellie R Machlus; Wendy Y Chen; Joseph E Italiano; Elisabeth M Battinelli Journal: Blood Adv Date: 2019-01-22
Authors: Tessa J Barrett; Martin Schlegel; Felix Zhou; Mike Gorenchtein; Jennifer Bolstorff; Kathryn J Moore; Edward A Fisher; Jeffrey S Berger Journal: Sci Transl Med Date: 2019-11-06 Impact factor: 17.956
Authors: Nathaniel R Smilowitz; Gregory Katz; Jill P Buyon; Robert M Clancy; Jeffrey S Berger Journal: J Thromb Thrombolysis Date: 2018-01 Impact factor: 2.300
Authors: Gregory Katz; Nathaniel R Smilowitz; Ashira Blazer; Robert Clancy; Jill P Buyon; Jeffrey S Berger Journal: Mayo Clin Proc Date: 2019-07-11 Impact factor: 7.616
Authors: Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard Journal: Nat Rev Rheumatol Date: 2018-03-21 Impact factor: 20.543
Authors: Michael S Garshick; Pamela B Rosenthal; Elliot Luttrell-Williams; Bruce N Cronstein; Jeffrey S Berger Journal: Rheumatology (Oxford) Date: 2021-11-03 Impact factor: 7.580